Biotech stocks rally; foreign investors’ KOSDAQ 2 trillion won 5,000 hundred million won in net purchases

2026In 5 of 22–23, biotech-related stocks generally rose on KOSDAQ. Some shares moved sharply following clinical trial results and the release of conference abstracts. During the same period, foreign investors were reported to have made large net purchases of KOSDAQ shares.

Active pharmaceutical ingredient manufacturers saw orders increase and performance improve as the effects of factory expansions took hold. The companies said that higher capacity utilization following the expansions and unit-price contracts were driving the increase in orders. Revenue and order reports from the companies concerned were reflected in recent quarterly results.

D&D Pharmatech’s share price rose on optimism related to the European Association for the Study of the Liver congress. Investor attention is focused on the release of clinical trial results. The company explained the data it submitted to the congress.

GI Innovation’s share price rose after the ASCO abstract was released. The company reported an objective response rate (ORR) 40% for its immuno-oncology drug in kidney cancer. The ASCO abstract and related clinical indicators affected the share-price movement.

Ingenia Therapeutics, a Korean-American biotech company, received approval for a preliminary listing review in the United States. The company disclosed plans to proceed with the listing process. The disclosure attracted investor interest.

During the same period, foreign investors made net purchases worth about 2 trillion 5,000 hundred million won on KOSDAQ. The net purchases were reported to have focused on the semiconductor, robotics, and biotech sectors. Trading value and the concentration of purchases by sector affected market trends.